Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
Status:
Completed
Trial end date:
1999-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate a reduction in the proportion of new
vertebral fractures in postmenopausal women with osteoporosis following 3-years of treatment
with 20 and 40 mcg/day of teriparatide plus calcium and vitamin D compared with calcium and
vitamin D alone.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Calcium Calcium, Dietary Ergocalciferols Teriparatide Vitamin D Vitamins